Ernexa Therapeutics Inc.: Form 10-Q for the period ended Mar 31, 2020
Filed with the SEC on May 20, 2020 and accepted by EDGAR at May 20, 2020, 16:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-01-01 to 2020-03-31 | $2.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Selling, general and administrative | 3 months2020-01-01 to 2020-03-31 | $3.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-01-01 to 2020-03-31 | −$2.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2020-01-01 to 2020-03-31 | −$19.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-01-01 to 2020-03-31 | −$1.2m | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months2020-01-01 to 2020-03-31 | −$1.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2020-01-01 to 2020-03-31 | $19.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-03-31 | $2.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-03-31 | $4.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-03-31 | $11.0m | us-gaap:Assets |
| Current liabilities | At period end2020-03-31 | $4.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-03-31 | $7.2m | us-gaap:Liabilities |
| Current portion of debt | At period end2020-03-31 | $2.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2020-03-31 | $3.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-20-009524. Last ingested by Listed: Nov 6, 2026, 17:52 ET. Listed shows no prices and gives no investment advice.